Case Histories of Significant Medical Advances: Tamoxifen

19 Pages Posted: 24 Aug 2020 Last revised: 9 Jun 2021

See all articles by Amar Bhide

Amar Bhide

Tufts University - The Fletcher School of Law and Diplomacy

Srikant Datar

Harvard University - Accounting & Control Unit

Katherine Stebbins

Harvard University - Business School (HBS)

Date Written: May 15, 2021

Abstract

Our case history describes the development of tamoxifen, considered a “gold standard” treatment for millions of breast cancer patients. Specifically, we describe breast cancer treatments prior to tamoxifen’s development; the initial development of tamoxifen from 1960 to 1973; tamoxifen’s adoption as an adjuvant breast cancer treatment between 1973 and 1985; and the extension of tamoxifen’s use to include preventative treatment, between 1986 and 2002.

Suggested Citation

Bhide, Amar and Datar, Srikant and Stebbins, Katherine, Case Histories of Significant Medical Advances: Tamoxifen (May 15, 2021). Harvard Business School General Management Unit Working Paper No. 20-134, Harvard Business School Accounting & Management Unit Working Paper No. 20-134, Available at SSRN: https://ssrn.com/abstract=3679645 or http://dx.doi.org/10.2139/ssrn.3679645

Amar Bhide

Tufts University - The Fletcher School of Law and Diplomacy ( email )

Cabot 505
160 Packard Avenue
Medford, MA 02155
United States
617-229-5050 (Phone)

HOME PAGE: http://www.bhide.net

Srikant Datar (Contact Author)

Harvard University - Accounting & Control Unit ( email )

Soldiers Field
Boston, MA 02163
United States
617-495-6543 (Phone)
617-496-7363 (Fax)

Katherine Stebbins

Harvard University - Business School (HBS) ( email )

Soldiers Field Road
Morgan 270C
Boston, MA 02163
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
21
Abstract Views
329
PlumX Metrics